Analyst Price Targets — KARD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 11:42 am | — | Leerink Partners | $37.00 | $24.64 | TheFly | Kardigan initiated with an Outperform at Leerink |
| July 13, 2026 9:33 am | — | Jefferies | $40.00 | $24.64 | TheFly | Kardigan initiated with a Buy at Jefferies |
Latest News for KARD
Kardiganâ¢, Inc. (Nasdaq: KARD) (âKardiganâ or âthe Companyâ), a clinical-stage precision therapeutics company developing medicines that target the roo
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #CVD--Kardigan™, Inc. (Nasdaq: KARD) today reported financial results from the second quarter ended June 30, 2026, and provided recent business updates.
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced the closing of its initial public offering.
Kardigan's shares rose 1.6% in their Nasdaq debut on Thursday, after the heart drug developer raised $400 million in an upsized U.S. initial public offering.
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KARD.
U.S. House Trading
No House trades found for KARD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.